• Mission

    Spring Bank is devoted to pioneering its revolutionary SMNH chemistry platform to discover and develop a new generation of medicines to improve the lives of patients worldwide.
  • Our Technology

    Our proprietary small molecule nucleic acid hybrids (SMNH) chemistry platform produces a class of compounds designed to selectively target and modulate the activity of specific proteins implicated in various disease states with the favorable drug-like qualities of traditional small molecules.
  • Clinical Trials

    Get the latest information about our ongoing clinical trials.
  • Latest News

      • JUNE 7, 2017

      Spring Bank Provides Update on its Next-Generation STING Platform and Announces Publication of an Abstract at ASCO Related to its Lead STING Agonist Candidate, SB 11285

      SB 11285 Shows Potent and Durable, Immune-Mediated Anti-Tumor Activity in Both Lymphoma and Colon Cancer Animal Models
      HOPKINTON, Mass., June 07, 2017 (GLOBE NEWSWIRE) — Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH) announced today that an abstract regarding its lead STING agonist candidate was published at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting held June 2 – 6th in Chicago, IL.  The Spring Bank abstract was titled “Preclinical Studies of SB 11285, a Novel STING (STimulator of INterferon Genes) Agonist for Immuno-Oncology.” The abstract includes results from the efficacy studies of SB 11285 in the syngeneic mouse models of A20 lymphoma and CT26 colon cance…

      Read more